U.S. Supreme Court rejects GlaxoSmithKline; FDA e-cig regulations under further scrutiny
Posted by Matt Rowland on Jun 13, 2016
A former Commissioner of the Food and Drug Administration (FDA), Margaret Hamburg, is facing allegations of racketeering, conspiracy, and colluding to conceal possibly deadly information regarding the drug Levaquin. Under the federal Racketeer Influenced and Corrupt Organizations (RICO) law, Hamburg could face possible prison time, and the FDA might be forced to pay nearly $1 billion in punitive damages.
Meanwhile, the United States Supreme Court recently rejected a motion to dismiss a court case against pharmaceutical company GlaxoSmithKline that claims the Big Pharm conglomerate intentionally concealed safety risks about a Diabetes medication called Avandia. GlaxoSmithKline is accused of manipulating scientific literature, falsifying advertisement campaigns, and issuing misleading statements about the drug in order to increase sales.
The FDA and GlaxoSmithKline: A pattern of deceptive and devious behavior
While these two cases have nothing whatsoever to do with electronic cigarettes, many in the vaping community believe that this series of new lawsuits only demonstrates a pattern of deceptive and devious behavior that is supported and encouraged within the FDA from the top down. Mitch Zeller, organizer behind the recently announced FDA e-cig regulations, was once a political consultant for GlaxoSmithKline, which incidentally is the manufacturer of Nicorette Gum. Pro-vaping advocates have long suspected that Zeller only pushed for the FDA e-cig regulations as an easy way of eliminating the vaping industry, the primary competitor to Nicorette Gum and other “quit smoking” products.
(Related Article: MITCH ZELLER AND JACK HENNINGFIELD: THE BIG PHARMA CONSPIRACY BEHIND THE FDA E-CIG REGULATIONS)
Margaret Hamburg: Long history of ‘conflict of interest’
While Hamburg has never been employed by GlaxoSmithKline, her husband once ran a hedge fund named Renaissance Technologies (RT) which held tens of millions of dollars in stock in Big Pharma’s Alkermes, the manufacturer of the drug Zohydro. In 2012, Hamburg approved the drug on behalf of the FDA even though an advisory panel voted 11 to 2 against approval due to concerns of possible overdosing by its patients.
With the Hamburg-provided “FDA stamp of approval,” Alkermes stock prices soared, and Hamburg made millions. To add insult to injury, the company also released a second drug that treats the very same patients who would eventually become addicted to Zohydro. In short, Hamburg approved two drugs that made her a very rich woman - one drug that addicted the millions of patients and the second drug that “cured” them.
Sen. Ron Johnson: An unlikely ally of the vaping industry
For many in the vaping industry, the Machiavellian partnership between Big Pharma and The FDA is one that cannot be ignored any longer. Hamburg’s recent lawsuit involving the RICO charges seems to show a continuous abuse of authority that dates back as far as 1996. And the FDA’s consistent hiring of Big Pharm ex-employees seems to indicate another significant conflict of interest, as well.
Fortunately, the vaping industry has at least one political supporter in its corner. Sen. Ron Johnson from Wisconsin is a member of the Committee on Homeland Security and Governmental Affairs. Since the May 5 announcement of the FDA e-cig regulations, Sen. Johnson has issued two somewhat aggressively worded letters to the FDA demanding access to the scientific research and other data that was used to write them.
Johnson is also calling for the FDA to be more “transparent and accountable in its regulatory actions.” Will “The Badger State Senator” finally be the one to uncover the dishonest business practices that seemingly run rampant throughout the FDA? Only time will tell. But should the vaping industry decide to take its case to the U.S. Supreme Court, the current rejection for dismissal of the GlaxoSmithKline case shows a second glimmer of hope.
Posted by Matt Rowland on Jun 13, 2016
A former Commissioner of the Food and Drug Administration (FDA), Margaret Hamburg, is facing allegations of racketeering, conspiracy, and colluding to conceal possibly deadly information regarding the drug Levaquin. Under the federal Racketeer Influenced and Corrupt Organizations (RICO) law, Hamburg could face possible prison time, and the FDA might be forced to pay nearly $1 billion in punitive damages.
Meanwhile, the United States Supreme Court recently rejected a motion to dismiss a court case against pharmaceutical company GlaxoSmithKline that claims the Big Pharm conglomerate intentionally concealed safety risks about a Diabetes medication called Avandia. GlaxoSmithKline is accused of manipulating scientific literature, falsifying advertisement campaigns, and issuing misleading statements about the drug in order to increase sales.
The FDA and GlaxoSmithKline: A pattern of deceptive and devious behavior
While these two cases have nothing whatsoever to do with electronic cigarettes, many in the vaping community believe that this series of new lawsuits only demonstrates a pattern of deceptive and devious behavior that is supported and encouraged within the FDA from the top down. Mitch Zeller, organizer behind the recently announced FDA e-cig regulations, was once a political consultant for GlaxoSmithKline, which incidentally is the manufacturer of Nicorette Gum. Pro-vaping advocates have long suspected that Zeller only pushed for the FDA e-cig regulations as an easy way of eliminating the vaping industry, the primary competitor to Nicorette Gum and other “quit smoking” products.
(Related Article: MITCH ZELLER AND JACK HENNINGFIELD: THE BIG PHARMA CONSPIRACY BEHIND THE FDA E-CIG REGULATIONS)
Margaret Hamburg: Long history of ‘conflict of interest’
While Hamburg has never been employed by GlaxoSmithKline, her husband once ran a hedge fund named Renaissance Technologies (RT) which held tens of millions of dollars in stock in Big Pharma’s Alkermes, the manufacturer of the drug Zohydro. In 2012, Hamburg approved the drug on behalf of the FDA even though an advisory panel voted 11 to 2 against approval due to concerns of possible overdosing by its patients.
With the Hamburg-provided “FDA stamp of approval,” Alkermes stock prices soared, and Hamburg made millions. To add insult to injury, the company also released a second drug that treats the very same patients who would eventually become addicted to Zohydro. In short, Hamburg approved two drugs that made her a very rich woman - one drug that addicted the millions of patients and the second drug that “cured” them.
Sen. Ron Johnson: An unlikely ally of the vaping industry
For many in the vaping industry, the Machiavellian partnership between Big Pharma and The FDA is one that cannot be ignored any longer. Hamburg’s recent lawsuit involving the RICO charges seems to show a continuous abuse of authority that dates back as far as 1996. And the FDA’s consistent hiring of Big Pharm ex-employees seems to indicate another significant conflict of interest, as well.
Fortunately, the vaping industry has at least one political supporter in its corner. Sen. Ron Johnson from Wisconsin is a member of the Committee on Homeland Security and Governmental Affairs. Since the May 5 announcement of the FDA e-cig regulations, Sen. Johnson has issued two somewhat aggressively worded letters to the FDA demanding access to the scientific research and other data that was used to write them.
Johnson is also calling for the FDA to be more “transparent and accountable in its regulatory actions.” Will “The Badger State Senator” finally be the one to uncover the dishonest business practices that seemingly run rampant throughout the FDA? Only time will tell. But should the vaping industry decide to take its case to the U.S. Supreme Court, the current rejection for dismissal of the GlaxoSmithKline case shows a second glimmer of hope.
